Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib [Melanoma]
Conclusion Dabrafenib plus trametinib results in a median OS of more than 2 years in BRAF inhibitor–naive patients with BRAF V600 mutation–positive metastatic melanoma, and approximately 20% were progression free at 3 years. Durable responses occurred in patients with good prognostic features at baseline, which may be predictive. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Long, Weber, Infante, Kim, Daud, Gonzalez, Sosman, Hamid, Schuchter, Cebon, Kefford, Lawrence, Kudchadkar, Burris, Falchook, Algazi, Lewis, Puzanov, Ibrahim, Sun, Cunningham, Kline, Del Buono, McDowell, Patel, Flaherty Tags: Chemotherapy Melanoma Source Type: research

CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Childrens Oncology Group Genome-Wide Association Study [Pediatric Oncology]
Purpose Interindividual variability in the dose-dependent association between anthracyclines and cardiomyopathy suggests that genetic susceptibility could play a role. The current study uses an agnostic approach to identify genetic variants that could modify cardiomyopathy risk. Methods A genome-wide association study was conducted in childhood cancer survivors with and without cardiomyopathy (cases and controls, respectively). Single-nucleotide polymorphisms (SNPs) that surpassed a prespecified threshold for statistical significance were independently replicated. The possible mechanistic significance of validated SNP(s) ...
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Wang, Sun, Quinones-Lombrana, Singh, Landier, Hageman, Mather, Rotter, Taylor, Chen, Armenian, Winick, Ginsberg, Neglia, Oeffinger, Castellino, Dreyer, Hudson, Robison, Blanco, Bhatia Tags: Genetic epidemiology, Long Term Survival & Late Effects Pediatric Oncology Source Type: research

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Childrens Oncology Group Randomized Trial Pediatric Oncology Group 9404 [Pediatric Oncology]
Conclusion Dexrazoxane was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of toxicities, and was not associated with a significant increase in second malignancies with this doxorubicin-containing chemotherapy regimen. We recommend dexrazoxane as a cardioprotectant for children and adolescents who have malignancies treated with anthracyclines. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Asselin, Devidas, Chen, Franco, Pullen, Borowitz, Hutchison, Ravindranath, Armenian, Camitta, Lipshultz Tags: Chemotherapy, Chemotherapy, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Long Term Survival & Late Effects, Outcomes Research, Supportive Care Pediatric Oncology Source Type: research

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database [Gastrointestinal Cancer]
Conclusions These analyses support the addition of oxaliplatin to fluoropyrimidine-based adjuvant therapy in patients with stage III disease and underscore the need for adequate surveillance of patients with colon cancer during the first 3 years after adjuvant therapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Shah, Renfro, Allegra, Andre, de Gramont, Schmoll, Haller, Alberts, Yothers, Sargent Tags: Prognostic Studies, Chemotherapy Gastrointestinal Cancer Source Type: research

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study [Urologic Oncology]
Conclusion Atezolizumab demonstrated a manageable safety profile and promising antitumor activity in patients with metastatic RCC. Correlative studies identified potential predictive and pharmacodynamic biomarkers. These results have guided ongoing studies and combinations with atezolizumab in RCC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: McDermott, Sosman, Sznol, Massard, Gordon, Hamid, Powderly, Infante, Fasso, Wang, Zou, Hegde, Fine, Powles Tags: Clinical Trials, Phase I and Clinical Pharmacology, Translational Oncology, Genitourinary, Cancer Biomarkers, Gene Expression and Profiling, Immunology/Immunobiology, Phase I and Clinical Pharmacology Urologic Oncology Source Type: research

Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer [Urologic Oncology]
Purpose Given that randomized trials exploring adjuvant chemotherapy for bladder cancer have been underpowered and/or terminated prematurely, yielding inconsistent results and creating an evidence gap, we sought to compare the effectiveness of cystectomy versus cystectomy plus adjuvant chemotherapy in real-world patients. Patients and Methods We conducted an observational study to compare the effectiveness of adjuvant chemotherapy versus observation postcystectomy in patients with pathologic T3-4 and/or pathologic node-positive bladder cancer using the National Cancer Data Base. We compared overall survival using propensi...
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Galsky, Stensland, Moshier, Sfakianos, McBride, Tsao, Casey, Boffetta, Oh, Mazumdar, Wisnivesky Tags: Surgery, Chemotherapy, Combined Modality Therapy Urologic Oncology Source Type: research

Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study [Treatment-Related Complications]
Conclusion Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Ganz, Petersen, Bower, Crespi Tags: Hormonal Therapy, Menopausal Symptoms, Quality of Life Treatment-Related Complications Source Type: research

Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer [Treatment-Related Complications]
Conclusion The incidence of all grades of rash did not differ statistically among the three arms, so the trial was negative. The incidence of grade 3 skin toxicities was reduced in patients who were treated with prophylactic minocycline or reactive treatment. Efficacy was not compromised. Prophylactic minocycline and reactive treatment are both acceptable options for the necessary treatment of erlotinib-induced rash in the second- or third-line setting of metastatic NSCLC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Melosky, Anderson, Burkes, Chu, Hao, Ho, Ho, Lam, Lee, Leighl, Murray, Sun, Winston, Laskin Tags: Supportive Care, Translational Oncology, Lung Treatment-Related Complications Source Type: research

Inferring the Effects of Cancer Treatment: Divergent Results From Early Breast Cancer Trialists Collaborative Group Meta-Analyses of Randomized Trials and Observational Data From SEER Registries [Breast Cancer]
Conclusion This study of mortality after radiotherapy for breast cancer found strikingly divergent results between the Early Breast Cancer Trialists’ Collaborative Group meta-analyses of randomized data and the SEER observational data, even when efforts had been made to remove confounding and selection biases. Nonrandomized comparisons are liable to provide misleading estimates of treatment effects. Therefore, they need careful justification every time they are used. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Henson, Jagsi, Cutter, McGale, Taylor, Darby Tags: Radiation, Clinical Trials, Population and observational studies (SEER, WHI observational, etc.), Radiation Oncology, Statistics in Oncology Breast Cancer Source Type: research

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations [Rapid Communications]
Conclusion Mutational events of MET leading to exon 14 skipping are frequent and potentially targetable events in PSC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Liu, Jia, Stoopler, Shen, Cheng, Chen, Mansukhani, Koul, Halmos, Borczuk Tags: Rapid Communications, Translational Oncology, Rapid Communications, Oncogenes Source Type: research

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial [Rapid Communications]
Purpose This multicenter study, to our knowledge, is the first phase III trial to compare trabectedin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior therapy with an anthracycline and at least one additional systemic regimen. Patients and Methods Patients were randomly assigned in a 2:1 ratio to receive trabectedin or dacarbazine intravenously every 3 weeks. The primary end point was overall survival (OS), secondary end points were disease control—progression-free survival (PFS), time to progression, objective response rate, and duration of response—as well as safety and ...
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Demetri, von Mehren, Jones, Hensley, Schuetze, Staddon, Milhem, Elias, Ganjoo, Tawbi, Van Tine, Spira, Dean, Khokhar, Park, Knoblauch, Parekh, Maki, Patel Tags: Rapid Communications, Chemotherapy, Rhabdo & Other Soft Tissue Sarcomas: Source Type: research

Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never? [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 64-year-old man with a history of cigarette smoking but no significant comorbidities presented with hem...
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Sonpavde, Gordetsky, Lockhart, Nix Tags: Oncology Grand Rounds Source Type: research

Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Pal, Agarwal, Grivas, Choueiri Tags: Chemotherapy EDITORIALS Source Type: research

Pre-Emptive or Reactive Treatment of Cutaneous Rash Induced by Epidermal Growth Factor Receptor Inhibitors: Does It Matter? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Zalcman, Brosseau, Gounant Tags: EDITORIALS Source Type: research

Randomized Clinical Trials and Observational Studies: Is There a Battle? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Chavez-MacGregor, Giordano Tags: Surgery, Radiation, Population and observational studies (SEER, WHI observational, etc.) EDITORIALS Source Type: research

Trabectedin and the L-Sarcomas: A Decade-Long Odyssey [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Schwartz Tags: Chemotherapy EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Fathi, Lin, Durazzo, Piris, Sadrzadeh, Bernardo, Borger, McAfee, Kroshinsky, Chen Tags: Biological Therapy DIAGNOSIS IN ONCOLOGY Source Type: research

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Hill, Shen, El Rassi, Khoury Tags: Combined Modality, Combined Therapy DIAGNOSIS IN ONCOLOGY Source Type: research

Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - March 2, 2016 Category: Cancer & Oncology Authors: Schrader, Stratton, Murali, Laitman, Cavallone, Offit, Wen, Thomas, Shah, Rau-Murthy, Manschreck, Salo-Mullen, Otegbeye, Corines, Zhang, Norton, Hudis, Klein, Kauff, Robson, Stadler, Haber, Lipkin, Friedman, Foulkes, Altshuler, Vijai, Offit Tags: Molecular epidemiology, Hereditary Cancers & Genetic Predisposition DIAGNOSIS IN ONCOLOGY Source Type: research

Reply to Y.H. Kim and M. Mishima [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Ahn, Park Tags: CORRESPONDENCE Source Type: research

Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Kim, Mishima Tags: CORRESPONDENCE Source Type: research

Reply to H.J.A. Adams and T.C. Kwee [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Mamot Tags: CORRESPONDENCE Source Type: research

Both Interim and End-of-Treatment 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Scans Have Low Value in Diffuse Large B-Cell Lymphoma [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Adams, Kwee Tags: CORRESPONDENCE Source Type: research

Reply to B. Biswas and D. Dabkara [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Penel, Ray-Coquard Tags: CORRESPONDENCE Source Type: research

Bevacizumab in Advanced Angiosarcoma: What Is the Reality? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Biswas, Dabkara Tags: CORRESPONDENCE Source Type: research

Building a Rapid Learning Health Care System for Oncology: Why CancerLinQ Collects Identifiable Health Information to Achieve Its Vision [SPECIAL ARTICLE]
The ever-increasing volume of scientific discoveries, clinical knowledge, novel diagnostic tools, and treatment options juxtaposed with rising costs in health care challenge physicians to identify, prioritize, and use new information rapidly to deliver efficient and high-quality care to a growing and aging patient population. CancerLinQ, a rapid learning health care system in oncology, is an initiative of the American Society of Clinical Oncology and its Institute for Quality that addresses these challenges by collecting information from the electronic health records of large numbers of patients with cancer. CancerLinQ is ...
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Shah, Stewart, Kolacevski, Michels, Miller Tags: Bioinformatics, Quality of Care SPECIAL ARTICLE Source Type: research

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Childrens Oncology Group Trial AAML0531 [Pediatric Oncology]
Purpose CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. Patients and Methods CD33 expression levels were prospectively quantified by multidimensional flow cytometry in 825 patients enrolled in Children’s Oncology Group AAML0531 and correlated with response to GO. Results Patients with low CD33 expression (lowest quartile of expression [Q1]) had no benefit with the addition of GO to conventional chemothera...
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Pollard, Loken, Gerbing, Raimondi, Hirsch, Aplenc, Bernstein, Gamis, Alonzo, Meshinchi Tags: Acute Non-Lymphoblastic Leukemia/MDS/CML Pediatric Oncology Source Type: research

Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study [Pediatric Oncology]
Conclusion None of the methods of primary tumor response assessment was predictive of outcome. Measurement of three dimensions followed by calculation of resultant volume is more complex than measurement of a single dimension. Primary tumor response in children with high-risk neuroblastoma should therefore be evaluated in accordance with RECIST criteria, using the single longest dimension. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Bagatell, McHugh, Naranjo, Van Ryn, Kirby, Brock, Lyons, States, Rojas, Miller, Volchenboum, Simon, Krug, Sarnacki, Valteau-Couanet, von Schweinitz, Kammer, Granata, Pio, Park, Nuchtern Tags: Neuroblastoma Pediatric Oncology Source Type: research

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma [Neuro-oncology]
Conclusion The results of this analysis do not justify the use of VPA or LEV for reasons other than seizure control in patients with newly diagnosed glioblastoma outside clinical trials. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Happold, Gorlia, Chinot, Gilbert, Nabors, Wick, Pugh, Hegi, Cloughesy, Roth, Reardon, Perry, Mehta, Stupp, Weller Tags: Brain Tumors, Radiation, Chemotherapy Neuro-oncology Source Type: research

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [Thoracic Oncology]
Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of patients with cancer with MET exon 14 mutations. Patients and Methods We interrogated next-generation sequencing results from 6,376 cancers to identify those harboring MET exon 14 mutations. Clinical characteristics of MET exon 14 mutated NSCLCs were compared with those of NSCLCs with activating mutations in KRAS and EGFR. Co-occurring genomic mutations and copy number alterations were identified. ...
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Awad, Oxnard, Jackman, Savukoski, Hall, Shivdasani, Heng, Dahlberg, Janne, Verma, Christensen, Hammerman, Sholl Tags: Translational Oncology, Cancer Biomarkers, Oncogenes Thoracic Oncology Source Type: research

Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy [Urologic Oncology]
Conclusion Our data suggest that the concept of conditional survival applies to patients with MT-GCT treated with curative therapy. Patients with MT-GCT who survived and remained disease free more than 2 years after the diagnosis had an excellent chance of staying alive and disease free in additional subsequent years, regardless of the initial IGCCCG risk stratification. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Ko, Bernard, Tran, Li, Asif, Stukalin, Lee, Day, Alimohamed, Sweeney, Bedard, Heng Tags: Chemotherapy, Diagnosis & Staging, Outcomes Research Urologic Oncology Source Type: research

Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study [Gynecologic Cancer]
Conclusion Single-agent volasertib showed antitumor activity in patients with ovarian cancer. AEs in patients receiving volasertib were mainly hematologic and manageable. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Pujade-Lauraine, Selle, Weber, Ray-Coquard, Vergote, Sufliarsky, Del Campo, Lortholary, Lesoin, Follana, Freyer, Pardo, Vidal, Tholander, Gladieff, Sassi, Garin-Chesa, Nazabadioko, Marzin, Pilz, Joly Tags: Chemotherapy Gynecologic Cancer Source Type: research

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907 [Breast Cancer]
Conclusion Excluding from clinical trials patients with renal insufficiency but good performance status on the basis of concern of excessive hematologic toxicity or poor outcomes may not be justified with appropriate dosing modifications. Results should be considered in the design of clinical trials for older patients. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Lichtman, Cirrincione, Hurria, Jatoi, Theodoulou, Wolff, Gralow, Morganstern, Magrinat, Cohen, Muss Tags: Chemotherapy, Geriatric Oncology Breast Cancer Source Type: research

Impact of Ipsilateral Blood Draws, Injections, Blood Pressure Measurements, and Air Travel on the Risk of Lymphedema for Patients Treated for Breast Cancer [Breast Cancer]
Purpose The goal of this study was to investigate the association between blood draws, injections, blood pressure readings, trauma, cellulitis in the at-risk arm, and air travel and increases in arm volume in a cohort of patients treated for breast cancer and screened for lymphedema. Patients and Methods Between 2005 and 2014, patients undergoing treatment of breast cancer at our institution were screened prospectively for lymphedema. Bilateral arm volume measurements were performed preoperatively and postoperatively using a Perometer. At each measurement, patients reported the number of blood draws, injections, blood pre...
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Ferguson, Swaroop, Horick, Skolny, Miller, Jammallo, Brunelle, OToole, Salama, Specht, Taghian Tags: Surgery, Radiation, Behavioral and Lifestyle Risk Factors Breast Cancer Source Type: research

Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy [Radiation Oncology]
Conclusion Patients receiving IMRT for HNC had improved outcomes when treated by higher-volume providers. These findings will better inform patients and providers when making decisions about treatment, and emphasize the critical importance of high-quality radiation therapy for optimal treatment of HNC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Boero, Paravati, Xu, Cohen, Mell, Le, Murphy Tags: Population and observational studies (SEER, WHI observational, etc.), Radiation, Radiation Oncology Source Type: research

Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy [Treatment-Related Complications]
Purpose To investigate the longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms (sx) and brain perfusion changes in patients with breast cancer. Interaction of CIPN-sx perfusion effects with known chemotherapy-associated gray matter density decrease was also assessed to elucidate the relationship between CIPN and previously reported cancer treatment–related brain structural changes. Methods Patients with breast cancer treated with (n = 24) or without (n = 23) chemotherapy underwent clinical examination and brain magnetic resonance imaging at the following three time points: be...
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Nudelman, McDonald, Wang, Smith, West, O'Neill, Zanville, Champion, Schneider, Saykin Tags: Chemotherapy, Outcomes Research Treatment-Related Complications Source Type: research

Randomized Trial Comparing Telephone Versus In-Person Weight Loss Counseling on Body Composition and Circulating Biomarkers in Women Treated for Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study [Cancer Prevention and Control]
Conclusion Both in-person and telephone counseling were effective weight loss strategies, with favorable effects on C-reactive protein levels. Our findings may help guide the incorporation of weight loss counseling into breast cancer treatment and care. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Harrigan, Cartmel, Loftfield, Sanft, Chagpar, Zhou, Playdon, Li, Irwin Tags: Epidemiology, Behavioral and Lifestyle Risk Factors Cancer Prevention and Control Source Type: research

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study [Rapid Communication]
Conclusion Alectinib is highly active and well tolerated in patients with advanced, crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Ou, Ahn, De Petris, Govindan, Yang, Hughes, Lena, Moro-Sibilot, Bearz, Ramirez, Mekhail, Spira, Bordogna, Balas, Morcos, Monnet, Zeaiter, Kim Tags: Rapid Communications, Lung Source Type: research

The Value of Considering Cost, and the Cost of Not Considering Value [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Saltz Tags: Cost Effectiveness, Quality of Care, Policy Analysis, Cost of Cancer Care COMMENTS AND CONTROVERSIES Source Type: research

Lymphedema Precautions: Time to Abandon Old Practices? [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 46-year-old premenopausal woman with a body mass index of 21 was found on screening mammography to have...
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Ahn, Port Tags: ONCOLOGY GRAND ROUNDS Source Type: research

Head and Neck Radiation Oncology: Is Busier Better? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Kim Tags: EDITORIALS Source Type: research

Painful Hands and Feet After Cancer Treatment: Inflammation Affecting the Mind-Body Connection [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Ganz, Dougherty Tags: Chemotherapy, Supportive Care, Quality of Life, Supportive Care EDITORIALS Source Type: research

Obesity and Breast Cancer Outcomes: How Much Evidence Is Needed to Change Practice? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Goodwin Tags: EDITORIALS Source Type: research

Emerging Options After Progression During Crizotinib Therapy [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Peters Tags: EDITORIALS Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Jain, Ok, Konoplev, Patel, Jorgensen, Estrov, Luthra, Kantarjian, Ravandi Tags: Leukemia, Lymphoma, Diagnosis & Staging, Chemotherapy, Biology & Immunology DIAGNOSIS IN ONCOLOGY Source Type: research

Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Venturini, Gambi, Di Lernia, Vanzulli, Bramerio, Bencardino, Amatu, Cipani, Forti, Tarenzi, Sartore-Bianchi, Pugliese, Siena Tags: Diagnosis & Staging, Diagnosis & Staging DIAGNOSIS IN ONCOLOGY Source Type: research

Hyperammonemic Encephalopathy Associated With GI Stromal Tumor [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 22, 2016 Category: Cancer & Oncology Authors: Chiu, Zaghiyan, Silberman Tags: Paraneoplastic Syndrome: Diagnosis & Staging, Surgery, Surgery DIAGNOSIS IN ONCOLOGY Source Type: research

Reply to A. Oguz et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - February 9, 2016 Category: Cancer & Oncology Authors: OSullivan, Holmes, Campbell, Bradbury, Zujewski, Gelber Tags: CORRESPONDENCE Source Type: research